LOGIN  |  REGISTER
Cue Biopharma

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

November 20, 2023 | Last Trade: US$1.97 0.01 -0.51

CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company’s pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Fireside chat and 1x1 Investor Meetings
Presentation: November 30, 2023 from 11:30 – 11:55 am ET

The presentations will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The Company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, a universal-MAPK program, as well as several early-stage programs. For more information, please visit www.immuneering.com

Media Contact:
Gina Nugent 
Nugent Communications 
617-460-3579 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investor Contacts: 
Laurence Watts 
Gilmartin Group 
619-916-7620 
This email address is being protected from spambots. You need JavaScript enabled to view it. 

or

Kiki Patel, PharmD 
Gilmartin Group 
332-895-3225
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Recursion

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB